Tag: Schoulepnikoff
OSE Immunotherapeutics strengthens its management team with the appointment of Laurence de Schoulepnikoff as Chief Business Officer – 12/20/2021 at 6:00 p.m.
Three directors with senior profiles also come to support the key drug development team. Nantes, France – December 20, 2021, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)…